Apicell Therapeutics Signs Agreement with Samsung Seoul Hospital for Joint Development of CGT

Yu Jongsang, CEO of Apicell Therapeutics, and Lee Gyuseong, Deputy Director of Research and Director of the Future Medicine Research Institute at Samsung Seoul Hospital (fourth from the left), are posing for a commemorative photo after signing a joint research cooperation agreement for "innovative research and development in the field of cell and gene therapy."

[Asia Economy Reporter Chunhee Lee] Daewoong Pharmaceutical and Apicell Therapeutics, a joint venture established with UK-based Abcam, announced on the 31st that they have signed a Memorandum of Understanding (MOU) for joint research collaboration on ‘innovative research and development in the field of cell and gene therapy’ with Samsung Medical Center.

The signing ceremony took place at Samsung Medical Center’s Irwon Station Campus, attended by Apicell Therapeutics CEO Yoojongsang, Kim Kinam from the research institute, Lee Gyuseong, Vice President of Research and Director of the Future Medicine Research Institute at Samsung Medical Center, Jang Yunsil, Director of the Cell and Gene Therapy Research Institute, and Lee Jihoon, Director of the Gene Therapy Research Center, who exchanged the agreement documents.

Through this MOU, both parties plan to mutually cooperate in ▲ exchanging trends and technical information in the field of gene-introduced mesenchymal stem cell therapeutics ▲ conducting joint national research projects related to the development of cell and gene therapies (CGT).

CEO Yoojongsang stated, “We are pleased to conduct this joint research with Samsung Medical Center’s Cell and Gene Therapy Research Institute,” adding, “We will strengthen research cooperation to open new paths for CGT development for rare and intractable diseases that face difficulties.” Vice President Lee Gyuseong said, “Innovation in the cell and gene therapy field is necessary for the development of CGT for rare and intractable diseases,” and added, “Through research cooperation with Apicell Therapeutics, which possesses gene introduction technology for mesenchymal stem cells, a foundation for fostering the cell and gene therapy field has been established.”

Apicell Therapeutics is a next-generation CGT development specialist company established in January 2020 as a joint investment by Daewoong Pharmaceutical and Abcam. By combining Daewoong Pharmaceutical’s stem cell platform (DW-MSC) and Abcam’s Affimer technology, they are developing a next-generation CGT (AFX platform) optimized for immune regulation. Their goal is to provide new and accessible cell therapies that treat intractable diseases and enable patients to lead healthy lives.

This content was produced with the assistance of AI translation services.